Tripep receives a patent for a new type of immune therapy directed against HIV-1

Tripep receives a patent for a new type of immune therapy directed against HIV-1

In the US Tripep has received a first patent protection for its RAS® peptides
that redirect natural antibodies to combat HIV-1. This is the second patent in
Tripeps platform technology RAS® which is based upon that all humans have
antibodies against the oligosaccharide Gal-alfa 1,3-Gal.

The oligosaccharide is present on all blood vessels in animals and all humans
have antibodies against this substance hence they are called natural antibodies.
These natural antibodies by themselves lack the ability to fight HIV-1. However,
these antibodies have potent biological functions. They cause graft rejection in
xeno-transplantations, i.e. they are the major reason why we cannot transplant
animal organs into humans.

Tripep has found that by coupling Gal-alfa 1,3-Gal  to synthetic peptides which
in turn bind to HIV-1, these natural antibodies can be redirected to destroy
HIV-1 and HIV-1 infected cells. This method paves the way not only for the
commercial development of a new class of HIV therapeutics, but also for other
infectious diseases or other situations where antibodies could be of potential
benefit, such as in cancer therapy.



For more information, please contact:

Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63, E-mail:
jan.nilsson@tripep.se

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28, E-mail:
anders.vahlne@ki.se


Tripep develops drugs against chronic disease based on proprietary and other
parties' patented and patent pending technologies. Tripep is focusing on the
following research projects; wound healing therapy ChronSeal and a therapeutic
vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology
platform. The Tripep share is admitted to trade on First North. Remium AB is
Certified Adviser for Tripep AB.  For more information, please refer to the
company's Website: www.tripep.se .